Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer (BRASTEGAC)
Adenocarcinoma of the Esophago-gastric Junction
About this trial
This is an interventional treatment trial for Adenocarcinoma of the Esophago-gastric Junction focused on measuring adenocarcinoma, esophago-gastric junction, dysphagia, brachytherapy, endoscopic stenting
Eligibility Criteria
Inclusion Criteria:
- Adenocarcinoma of the esophago-gastric junction defined as adenocarcinoma involving lower esophagus and upper stomach with epicenter of the primary tumor between 5cm above and 5cm below the anatomic esophago-gastric junction
- Inoperable cancer - locally advanced irresectible cancer, distant metastasis or patient's condition does not fit to undergo a curative therapy
- Dysphagia score 2-4
- Performance status 60-100
- Signed informed consent
Exclusion Criteria:
- Esophageal squamous cell carcinoma
- Esophageal adenocarcinoma
- Gastric cancer
- Performance status <60
- Instable cardiocirculatory or respiratory disorder
- Concurrent external beam radiation therapy
- Previous anticancer therapy related to current adenocarcinoma of the esophago-gastric junction
Sites / Locations
- Second Department of General & Gastrointestinal Surgery & Oncological Surgery of the Alimantary Tract, Medical University of LublinRecruiting
- St. John's Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Brachytherapy
Endoscopic Stenting
Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively